Dr. Will Rowland Voelzke, MD

Dr. Voelzke practices at Virginia Cancer Institute Incorporated in Richmond, Virginia.

Dr. Voelzke's NPI, 1023205697, was assigned on September 27, 2007. Dr. Voelzke graduated from Baylor College of Medicine in 2002. Dr. Voelzke holds Virginia license 0101250498.

Dr. Voelzke's primary practice is Virginia Cancer Institute Incorporated, at 7202 Glen Forest Dr, Richmond, VA 23226 in Henrico County. The practice phone is (804) 287-3000.

Dr. Voelzke's primary practice is Virginia Cancer Institute Incorporated in Richmond, Virginia. Dr. Voelzke is also affiliated with Chippenham Hospital. The medical group on file is Virginia Cancer Institute. Dmand AI also links Dr. Voelzke to 3 more hospitals and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Voelzke practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Voelzke's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Voelzke is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Voelzke's licenses on file in 3 states: Virginia, Georgia and Tennessee.

CMS data shows 76,761 Medicare services from Dr. Voelzke across 46 procedure codes in 2024, for 853 Medicare patients. Medicare paid $1,945,070 for them.

CMS counts 853 Medicare patients who saw Dr. Voelzke in 2024. The largest group is 65 to 74, with 373 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Voelzke's median patient age at 71, with 57% women.

In 2024, Dr. Voelzke wrote 1,332 Medicare Part D claims for 224 patients. 64% of them were for generic drugs. CMS names the drug for 1,035 of them, across 32 drugs with 11 or more claims each, at $2,870,046 in total drug cost. In 2023, CMS named 1,112 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Voelzke for performance year 2024, reported individually. Dr. Voelzke accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Voelzke as offering telehealth.

CMS Open Payments shows 359 general payments to Dr. Voelzke from 71 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 95% of the total. Janssen Pharmaceuticals, Inc paid the most, $738.

Dr. Voelzke graduated from Baylor College of Medicine in 2002.